Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Clin Exp Oncol Vol: 6 Issue: 4

Expression of Circulating Mir-206 in Patients with Lung and Head and Neck Cancers and its Association with Cancer Cachexia

Noorwati Sutandyo1*, Ririn Hariani2, Puspita Eka Wuyung3, Agus Rahmadi4, Achmad Mulawarman5, Cita Herawati6 and Ramadhan Ramli7

1Department of Internal Medicine, Dharmais Cancer Hospital, Jakarta, Indonesia

2Department of Clinical Nutrition, Dharmais Cancer Hospital, Jakarta, Indonesia

3Department of Anatomical Pathology, Faculty of Medicine, University of Indonesia, Depok, Indonesia

4Biomedical Science, Faculty of Medicine, University of Indonesia, Depok, Indonesia

5Department of Pulmonology, Dharmais Cancer Hospital, Jakarta, Indonesia

6Department of Ear Nose and Throat, Dharmais Cancer Hospital, Jakarta, Indonesia

7Department of Oncology Surgery, Dharmais Cancer Hospital, Jakarta, Indonesia

*Corresponding Author : Noorwati Sutandyo
Department of Hematology- Medical Oncology, Dharmais Cancer Hospital, Jl. Let. Jend. S. ParmanKav. 84- 86, Slipi, Jakarta 11420, Indonesia
Tel:
2356 / 021-568 1570
Fax: 021-5696 9561
E-mail: [email protected]

Received: May 24, 2017 Accepted: June 05, 2017 Published: June 12, 2017

Citation: Sutandyo N, Hariani R, Wuyung PE, Rahmadi A, Mulawarman A, et al. (2017) Expression of Circulating Mir-206 in Patients with Lung and Head and Neck Cancers and its Association with Cancer Cachexia. J Clin Exp Oncol 6:4. doi: 10.4172/2324-9110.1000191

Abstract

Background: cancer cachexia is a common problem found in advanced stage cases. Pathophysiology of cachexia is complicated, involving cytokines and regulator molecules such as microRNA (miRNA). MiR-206, a specific miRNA in skeletal muscle cells was thought to play important role in regulating skeletal muscle loss but have not been studied well in cachectic patients.

Objective: to evaluate the clinical significance of circulating miR-206 in cancer patients presenting with cancer cachexia.

Method: A cross-sectional study was performed in Dharmais Cancer Hospital, Jakarta between September and December 2015. Patients enrolled were lung and head and neck cancers. Cachexia was defined as body mass index less than 20 kg/m2. MiR-206 expression was assayed using quantitative real-time polymerase chain reaction (RT-PCR), whereas miR-16 served as internal control. The results were expressed as cycle threshold (CT) and fold change (FC) which was calculated using the 2-ΔΔCT method.

Results: Seventy patients were enrolled during the study period; consisting 37 (52.9%) lung 33 (47.1%) head and neck cancers. There were 31 (41.3%) patients presenting with cachexia. Serum miR-206 was overexpressed in cancer patients compare to normal healthy subjects. MicroRNA-206 expression was slightly up-regulated in cachectic patients than non-cachectic patients, i.e. FC=1.355 in lung cancers and FC=1.438 in head and neck cancers.

Conclusion: Circulating miR-206 is overexpressed advanced stage lung cancer as well as head and neck cancer patients. Increased circulating miR-206 in cachectic patients may reflect extensive skeletal muscle loss associated with cancer cachexia.

Keywords: Cancer cachexia; Circulating microRNA; Head and neck cancer; Lung cancer; MiR-206; Myo-miR

Track Your Manuscript

Share This Page

Media Partners